Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-03-10
2011-10-18
Yu, Misook (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S135100, C424S138100, C424S141100, C424S152100, C424S155100, C424S156100, C424S172100, C424S174100
Reexamination Certificate
active
08038996
ABSTRACT:
Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.
REFERENCES:
patent: 5593847 (1997-01-01), Barnett et al.
patent: 6297053 (2001-10-01), Stemmer
patent: 6759045 (2004-07-01), Goldenberg et al.
patent: 2002/0022031 (2002-02-01), Goldenberg et al.
patent: 2006/0024314 (2006-02-01), Stanners et al.
patent: 2004-505994 (2004-02-01), None
patent: WO 02/12347 (2002-02-01), None
patent: WO 03/068983 (2003-08-01), None
patent: WO 2004/092735 (2004-10-01), None
patent: WO 2005/073720 (2005-08-01), None
Mittal.B.B.et.al. Cancer. 78: 1861-1870, 1996.
Buchmann.I.et.al. Cancer Biotherapy and Radiopharmaceuticals. 17: 151-163, 2002.
Cersosimo,R.J. Am.J.health-syst pharm, 60:Part 1: 1531-1548 and part II: 1631-1641, 2003.
Ilantzis, C. et al., Neoplasia, 4(2): 151-163, 2002.
Ueno, A., et al., Med. Bull. Fukuoka Univ., 29(2): 83-93, 2002.
Alexis Biochemicals Newsletter, “Topix Latest Product Additions”, Issue 2. Fall 2004, pp. 1-8.
S. Holloway, et al., “A Clinically Relevant Model of Human Pancreatic Adenocarcinoma Identifies Patterns of Metastasis Associated with Alterations of the TGF-β/Smad4 Signaling Pathway”, International Journal of Gastrointestinal Cancer, vol. 33, No. 1, pp. 61-69, 2003.
H. Han, et al., “Identification of Differentially Expressed Genes in Pancreatic Cancer Cells Using cDNA Microarray”, Cancer Research 62, pp. 2890-2896, May 15. 2002.
W. Pearson, “Flexible Sequence Similarity Searching with the FASTA3 Program Package”, Methods in Molecular Biology, vol. 132: Bioinformatics Methods and Protocols, p. 185, 1999.
A. Pluckthun, et al., “Producing Antibodies inEscherichia coli: From PCR to Fermentation”, Antibody Engineering: A Practical Approach. IRL Press, Oxford, 1996. pp. 203-252.
V. Hoff, et al., “New Developments in the Treatment of Patients with Pancreatic Cancer”, Clinical Oncology Updates, 2001, vol. 4, No. 4, pp. 1-15.
H. Lynch, et al., “Familial Pancreatic Cancer: A Review”, Seminars Oncology, vol. 23, No. 2, Apr. 1996, pp. 251-275.
E. Jaffee, et al., “Focus on Pancreas Cancer”, Cancer Cell, 2002, vol. 2, No. 1, pp. 25-28.
N. Bardeesy, et al., “Pancreatic Cancer Biology and Genetics”, Nature Reviews Cancer, 2002, vol. 2, No. 12, pp. 897-909.
A. Cubilia, et al., “Morphological Patterns of Primary Nonendocrine Human Pancreas Carcinoma1”, Cancer Research, 1975, vol. 35, No. 8, pp. 2234-2248.
W. Klein, et al., “Direct Correlation Between Proliferative Activity and Dysplasia in Pancreatic Intraepithelial Neoplasia (PanIN): Additional Evidence for a Recently Proposed Model of Progression”, Modern Pathology, 2002, .vol. 15, No. 4, pp. 441-447.
C. Iacobuzio-Donahue, et al., “Exploring the Host Desmoplastic Response to Pancreatic Carcinoma”, American Journal of Pathology. vol. 160, No. 1, Jan. 2002. pp. 91-99.
M. Löhr, et al., “Transforming Growth Factor-β1 Induces Desmoplasia in an Experimental Model of Human Pancreatic Carcionoma1”, Cancer Research, 2001, vol. 61, No. 2, pp. 550-555.
J. Gardner-Thorpe, et al., “Differential Display of Expressed Genes in Pancreatic Cancer Cells”, Biochemical and Biophysical Research Communications, 2002. vol. 293, No. 1, pp. 391-395.
H. Friess, et al., “Microarrary-Based Identification of Differentially Expressed Growth-and Metastasis-Associated Genes in Pancreatic Cancer”, Cellular and Molecular Life Sciences, 2003, vol. 60, No. 6, pp. 1180-1199.
B. Ryu, et al., “Relationships and Differentially Expressed Genes Among Pancreatic Cancers Examined by Large-Scale Serial Analysis of Gene Expression1”, Cancer Research, Feb. 1, 2002, vol. 62, No. 3, pp. 819-826.
C. Iacobuzio-Donahue, et al., “Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays”, American Journal of Pathology, vol. 162, No. 4, Apr. 2003, pp. 1151-1162.
V. Smit, et al., “KRAS Codon 12 Mutations Occur Very Frequently in Pancreatic Adenocarcinomas”, Nucleic Acids Research, vol. 16, No. 16, 1988, pp. 7773-7782.
C. Griffin, et al., “Consistent Chromosome Abnormalities in Adenocarcinoma of the Pancreas1”, Cancer Research, 1995, vol. 55, No. 11, pp. 2394-2399.
K. Aoki, et al., “Suppression of Ki-ras p21 Levels Leading to Growth Inhibition of Pancreatic Cancer Cell Lines With Ki-ras Mutation But Not Those Without Ki-ras Mutation”, Molecular Carcinogenesis, 1997, vol. 20, pp. 251-258.
N. Ikeda, et al., “The Association of K-ras Gene Mutation and Vascular Endothelial Growth Factor Gene Expression in Pancreatic Carcinoma”, Cancer, Aug. 1, 2001, vol. 92, No. 3, pp. 488-499.
M. Wagner, et al., “A Murine Tumor Progression Model for Pancreatic Cancer Recapitulating the Genetic Alterations of the Human Disease”, Genes Development, 2001, vol. 15, pp. 286-293.
R. Sotilo, et al, et al., “Wide Spectrum of Tumors in Knock-In mice Carrying a Cdk4 Protein Insensitive to INK4 Inhibitors”, The EMBO Journal, 2001, vol. 20, No. 23, pp. 6637-6647.
N. Beauchemin, et al., “Nomenclature Announcement, Redefined Nomenclature for Members of the Carinoembryonic Antigen Family1”, Experimental Cell Research, 1999, vol. 252, No. 2, pp. 243-249.
M. Kuroki, et al., “Identification and Comparison of Residues Critical for Cell-Adhesion Activities of Two Neutrophil CD66 Antigens, CEACAM6 and CEACAM8”, 2001, vol. 70, No. 4, pp. 543-550.
A. Chevinsky, “CEA in Tumors of Other Than Colorectal Origin”, Seminars in Surgical Oncology, 1991, vol. 7, No. 3, pp. 162-166.
S. Schölzel, et al., “Carcinoembryonic Antigen Family Members CEACAM6 and CEACAM7 are Differentially Expressed in Normal Tissues and Oppositely Deregulated in Hyperplastic Colorectal Polyps and Early Adenomas”, American Journal of Pathology, 2000, vol. 156, No. 2, pp. 595-605.
C. Ordoñez, et al., “Human Carcinoembryonic Antigen Functions as a General Inhibitor of Anoikis1”, Cancer Research, Jul. 1, 2000, vol. 60, No. 13, pp. 3419-3424.
C.J. Sippel, et al., “Bile Acid Efflux Mediated by the Rat Liver Canalicular Bile Acid Transport/Ecto-Atpase Protein Requires Serine 503 Phosphorylation and Is Regulated by Tyrosine 488 Phosphyorylation”, The Journal of Biological Chemistry, 1994, vol. 269, No. 39, pp. 19539-19545.
J. Brümmer, et al., “Association of pp60C-SRCwith Biliary Glycoprotein (CD66a), An Adhesion Molecule of the Carcinoembryonic Antigen Family Downregulated in Colorectal Carcinomas”, Oncogene, 1995, vol. 11, No. 8, pp. 1649-1655.
N. Beauchemin, et al., “Association of Biliary Glycoprotein with Protein Tyrosine Phosphatase SHP-1 in Malignant Colon Epithelial Cells”, Oncogene, 1997, vol. 14, No. 7, pp. 783-790.
Y. Satow, et al., “Phosphocholine Binding Immunoglobulin Fab McPC603 an X-ray Diffraction Study at 2.7 Å”, J. Mol. Biol., 1986, vol. 190, No. 4, pp. 593-604.
G. Johnson, et al., “Kabat Database and Its Applications: Future Directions”, Nucleic Acids Research, 2001, vol. 29, No. 1, pp. 205-206.
D. Coomber, et al., “Generation of Anti-p53 Fab Fragments from Individuals with Colorectal Cancer Using Phage Display”, J. Immunol., 1999, vol. 163, No. 4, pp. 2276-2283.
A. Glas, et al., “Analysis of Rearranged Immunoglobulin Heavy Chain Variable Region Genes Obtained from a Bone Marrow Transplant (BMT) Recipient”, Clin. Exp. Immunol., 1997, vol. 107, No. 2, pp. 372-380.
S. Akashi, et al., “Structural Characterization of Mouse Monoclonal Antibody 13-1 Against a Porphyrin Derivative: Identification of a Disulfide Bond in CDR-H3 of Mab13-1”, Biochemical and Biophysical Research Communications, 1997, vol. 240, No. 3. pp. 566-572.
K. Alfthan, “Surface Plasmon Re
Holleran Anne
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
University of Arizona
Yu Misook
LandOfFree
Composition and method for cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262865